» Articles » PMID: 28584248

Fecal Occult Blood Test Results of the National Colorectal Cancer Screening Program in South Korea (2006-2013)

Overview
Journal Sci Rep
Specialty Science
Date 2017 Jun 7
PMID 28584248
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

There has been controversy regarding the clinical utility of fecal occult blood test (FOBT) as a screening tool for colorectal cancer (CRC) in the general population. The purpose of this study was to examine the results of Korea national CRC screening using FOBT from 2006 to 2013 and to evaluate the implementation of the program. We analyzed the results of FOBT, colonoscopy, and the side effects during colonoscopy for the subjects (n = 20,609,909) from the Korea National Health Insurance Cancer Screening database. For evaluation of Korea national CRC screening program implementation over the 8-year period, we calculated uptake rate, FOBT positivity rate, and subsequent test compliance rate. The overall uptake rate was 30.1%, with an increasing pattern from 2006 to 2011. A relatively higher FOBT positivity rate (6.4%) and lower subsequent test compliance rate (46.6%) were observed in comparison to the results previously reported in Western countries. Side effects reported within 3 months period after colonoscopy accounted for 0.17% of all procedures, with bleeding being the most prevalent type. Although the implementation of CRC screening program using FOBT in Korea seems successful, trends in key indicators for Korea national CRC screening program should be monitored continuously.

Citing Articles

Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.

Worthington J, van Wifferen F, Sun Z, de Jonge L, Lew J, Greuter M EClinicalMedicine. 2023; 62:102081.

PMID: 37538541 PMC: 10393619. DOI: 10.1016/j.eclinm.2023.102081.


Body Mass Index and Other Risk Factors Effects on Colon Cancer Prognosis in Pakistan.

Saleem S, Aleem I, Zeshan M, Bakar M, Atiq A, Tahseen M J Cancer Allied Spec. 2023; 8(2):477.

PMID: 37197568 PMC: 10187604. DOI: 10.37029/jcas.v8i2.477.


Cost-effectiveness analysis of a community-based colorectal cancer screening program in Shanghai, China.

Jiang H, Zhang P, Gu K, Gong Y, Peng P, Shi Y Front Public Health. 2022; 10:986728.

PMID: 36276354 PMC: 9586014. DOI: 10.3389/fpubh.2022.986728.


Colorectal Cancer Screening With High Risk-Factor Questionnaire and Fecal Immunochemical Tests Among 5, 947, 986 Asymptomatic Population: A Population-Based Study.

Zhang M, Zhao L, Zhang Y, Jing H, Wei L, Li Z Front Oncol. 2022; 12:893183.

PMID: 35712520 PMC: 9195590. DOI: 10.3389/fonc.2022.893183.


Disparities in Recommendations for Colorectal Cancer Screening Among Average-Risk Individuals: An Ecobiosocial Approach.

Syed Soffian S, Mohammed Nawi A, Hod R, Abdul Manaf M, Chan H, Hassan M Risk Manag Healthc Policy. 2022; 15:1025-1043.

PMID: 35599752 PMC: 9115807. DOI: 10.2147/RMHP.S359450.


References
1.
Binefa G, Garcia M, Mila N, Fernandez E, Rodriguez-Moranta F, Gonzalo N . Colorectal Cancer Screening Programme in Spain: Results of Key Performance Indicators After Five Rounds (2000-2012). Sci Rep. 2016; 6:19532. PMC: 4726304. DOI: 10.1038/srep19532. View

2.
Parente F, Marino B, Ardizzoia A, Ucci G, Ilardo A, Limonta F . Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province. Am J Gastroenterol. 2011; 106(11):1986-93. DOI: 10.1038/ajg.2011.185. View

3.
Hardcastle J, Chamberlain J, Robinson M, Moss S, Amar S, Balfour T . Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996; 348(9040):1472-7. DOI: 10.1016/S0140-6736(96)03386-7. View

4.
Shim J, Kim Y, Han M, Lee H, Choi K, Jun J . Results of colorectal cancer screening of the national cancer screening program in Korea, 2008. Cancer Res Treat. 2011; 42(4):191-8. PMC: 3021737. DOI: 10.4143/crt.2010.42.4.191. View

5.
Jung K, Won Y, Kong H, Oh C, Cho H, Lee D . Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47(2):127-41. PMC: 4398120. DOI: 10.4143/crt.2015.060. View